nach oben

Erschienen in:

01.01.2013 | Original Paper

Association Between Use of Specific Drugs and Antiretroviral Adherence: Findings from MACH 14

verfasst von: M. I. Rosen, A. C. Black, J. H. Arnsten, K. Goggin, R. H. Remien, J. M. Simoni, C. E. Golin, D. R. Bangsberg, H. Liu

Erschienen in: AIDS and Behavior | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

To determine the association between individual substances of abuse and antiretroviral adherence, analyses require a large sample assessed using electronic data monitoring (EDM). In this analysis, EDM data from 1,636 participants in 12 US adherence-focused studies were analyzed to determine the associations between recent use of various substances and adherence during the preceding 4 weeks. In bivariate analyses comparing adherence among patients who had used a specific substance to those who had not, adherence was significantly lower among those who had recently used cocaine, other stimulants or heroin but not among those who had used cannabis or alcohol. In multivariate analyses controlling for sociodemographics, amount of alcohol use and recent use of any alcohol, cocaine, other stimulants and heroin each was significantly negatively associated with adherence. The significant associations of cocaine, other stimulants, heroin, and alcohol use with adherence suggest that these are important substances to target with adherence-focused interventions.

Nur mit Berechtigung zugänglich

Crystal S, Sambamoorthi U, Moynihan PJ, McSpiritt E. Initiation and continuation of newer antiretroviral treatments among medicaid recipients with AIDS. J Gen Intern Med. 2001;16(12):850–9.PubMedCrossRef

Turner BJ, Fleishman JA, Wenger N, London AS, Burnam MA, Shapiro MF, et al. Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. J Gen Intern Med. 2001;16(9):625–33.PubMedCrossRef

Giordano TP, Gifford AL, White AC Jr, Suarez-Almazor ME, Rabeneck L, Hartman C, et al. Retention in care: a challenge to survival with HIV infection. Clin Infect Dis. 2007;44(11):1493–9.PubMedCrossRef

Hinkin CH, Castellon SA, Durvasula RS, Hardy DJ, Lam MN, Mason KI, et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology. 2002;59(12):1944–50.PubMedCrossRef

Moore RD, Keruly JC, Chaisson RE. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. J Acquir Immune Defic Syndr. 2004;35(1):46–51.PubMedCrossRef

Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134(10):968–77.PubMed

Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.PubMed

Press N, Tyndall MW, Wood E, Hogg RS, Montaner JS. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2002;31(3):15.

Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA. 1996;276(24):1955–6.PubMedCrossRef

10.

Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939–41.PubMedCrossRef

11.

Perno CF, Ceccherini-Silberstein F, De Luca A, Cozzi-Lepri A, Gori C, Cingolani A, et al. Virologic correlates of adherence to antiretroviral medications and therapeutic failure. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S118–22.PubMedCrossRef

12.

Malta M, Strathdee SA, Magnanini MMF, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction. 2008;103(8):1242–57.PubMedCrossRef

13.

Chander G, Himelhoch S, Moore RD, Chander G, Himelhoch S, Moore RD. Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. Drugs. 2006;66(6):769–89.PubMedCrossRef

14.

Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, Howard AA, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17(5):377–81.PubMed

15.

McNabb J, Ross JW, Abriola K, Turley C, Nightingale CH, Nicolau DP. Adherence to Highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis. 2001;33:700–5.PubMedCrossRef

16.

Hinkin CH, Barclay TR, Castellon SA, Levine AJ, Durvasula RS, Marion SD, et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 2007;11(2):185–94.PubMedCrossRef

17.

Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18:19–25.CrossRef

18.

Wagner G. Placebo practice trials: the best predictor of adherence readiness for HAART among drug users? HIV Clin Trials. 2003;4(4):269–81.PubMedCrossRef

19.

Golin C, Liu H, Hays R, Miller L, Beck C, Ickovics J, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002;17(10):756–65.PubMedCrossRef

20.

Howard AA, Arnsten JH, Lo Y, Vlahov D, Rich JD, Schuman P, et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS. 2002;16(16):2175–82.PubMedCrossRef

21.

Reinhard MJ, Hinkin CH, Barclay TR, Levine AJ, Marion S, Castellon SA, et al. Discrepancies between self-report and objective measures for stimulant drug use in HIV: cognitive, medication adherence and psychological correlates. Addict Behav. 2007;32(12):2727–36.PubMedCrossRef

22.

Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr. 2009;52(2):180–202.PubMedCrossRef

23.

Liu H, Wilson IB, Goggin K, Reynolds NR, Simoni JM, Golin CE, et al. MACH14: a multi-site collaboration on ART adherence among 14 institutions (Under Review).

24.

Berg KM, Demas PA, Howard AA, Schoenbaum EE, Gourevitch MN, Arnsten JH. Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med. 2004;19(11):1111–7.PubMedCrossRef

25.

Reback CJ, Larkins S, Shoptaw S. Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men. AIDS Care. 2003;15(6):775–85.PubMedCrossRef

26.

Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27(3):251–9.PubMed

27.

Epstein DH, Preston KL. Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? Past findings and more evidence against. Addiction. 2003;98(3):269–79.PubMedCrossRef

28.

Kalichman SC, Rompa D. HIV treatment adherence and unprotected sex practices in people receiving antiretroviral therapy. Sex Transm Infect. 2003;79(1):59–61.PubMedCrossRef

29.

Tucker JS, Burnam MA, Sherbourne CD, Kung F-Y, Gifford AL. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114(7):573–80.PubMedCrossRef

30.

Corless IB, Lindgren T, Holzemer W, Robinson L, Moezzi S, Kirksey K, et al. Marijuana effectiveness as an HIV self-care strategy. Clin Nurs Res. 2009;18(2):172–93.PubMedCrossRef

31.

De Jong BC, Prentiss D, McFarland W. MAchekano R, Israelski DM. Marijuana use and its association with adherence to antiretroviral therapy among HIV-infected persons with moderate to severe nausea. J Acquir Immune Defic Syndr. 2005;38(1):43–6.PubMedCrossRef

32.

Demas P, Schoenbaum EE, Wills TA, Doll LS, Klein RS. Stress, coping, and attitudes toward HIV treatment in injecting drug users: a qualitative study. AIDS Educ Prev. 1995;7(5):429–42.PubMed

33.

Rosen MI, Rigsby MO, Dieckhaus KD, Cramer JA. Effects of illicit drug use on adherence to prescribed antiretroviral medication. Am J Addict. 2003;12(5):455–8.PubMed

34.

Kosten TA, Rounsaville BJ. Sensitivity of psychiatric diagnosis based on the best estimate procedure. Am J Psychiatry. 1992;149(9):1225–7.PubMed

35.

Braithwaite RS, Conigliaro J, McGinnis KA, Maisto SA, Bryant K, Justice AC. Adjusting alcohol quantity for mean consumption and intoxication threshold improves prediction of nonadherence in HIV patients and HIV-negative controls. Alcohol Clin Exp Res. 2008;32(9):1645–51.PubMedCrossRef

36.

Lazo M, Gange SJ, Wilson TE, Anastos K, Ostrow DG, Witt MD, et al. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis. 2007;45(10):1377–85.PubMedCrossRef

Titel: Association Between Use of Specific Drugs and Antiretroviral Adherence: Findings from MACH 14
verfasst von: M. I. Rosen
A. C. Black
J. H. Arnsten
K. Goggin
R. H. Remien
J. M. Simoni
C. E. Golin
D. R. Bangsberg
H. Liu
Publikationsdatum: 01.01.2013
Verlag: Springer US
Erschienen in: AIDS and Behavior / Ausgabe 1/2013
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-011-0124-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Association Between Use of Specific Drugs and Antiretroviral Adherence: Findings from MACH 14

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

Update Innere Medizin

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

Evidence for the Reliability and Validity of the Internalized AIDS-Related Stigma Scale in Rural Uganda

Racial Discrimination, Social Support, and Sexual HIV Risk among Black Heterosexual Men

Communicating HIV Status in Sexual Interactions: Assessing Social Cognitive Constructs, Situational Factors, and Individual Characteristics Among South African MSM

Patterns of HIV Disclosure and Condom Use Among HIV-Infected Young Racial/Ethnic Minority Men Who Have Sex with Men

Correlates of Stigma among Rural Indian Women Living with HIV/AIDS

No Association Found Between Traditional Healer Use and Delayed Antiretroviral Initiation in Rural Uganda

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

Update Innere Medizin